Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02807636 · OUTCOME

Percentage of Participants With Anti-Therapeutic (Anti-Atezolizumab) Antibodies (ATAs)

Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma · Source last updated 2025-02-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
Not reported
Time frame
Up to approximately 35 months

What was measured

Percentage of participants with Anti-Therapeutic (Anti-Atezolizumab) Antibodies (ATAs).

Analysis population: The baseline ADA-evaluable population included participants who had a baseline ADA result. The post-baseline ADA-evaluable population included participants who had received at least one dose of the study treatment and who had at least one post-baseline ADA result.

Groups in this outcome

Atezolizumab+Gemcitabine+Carboplatin/Cisplatin

Participants received blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).

Atezolizumab Monotherapy

Eligible participants received open-label atezolizumab as monotherapy.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Atezolizumab+Gemcitabine+Carboplatin/Cisplatin434
Atezolizumab Monotherapy341

Reported measurements

Baseline evaluable participants

Analysis denominator · Participants

GroupSource count
Atezolizumab+Gemcitabine+Carboplatin/Cisplatin434
Atezolizumab Monotherapy341
Values in Percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Atezolizumab+Gemcitabine+Carboplatin/Cisplatin1.2Not reportedNot reportedNot reportedNot reported
Atezolizumab Monotherapy0.9Not reportedNot reportedNot reportedNot reported
Post-baseline evaluable participants

Analysis denominator · Participants

GroupSource count
Atezolizumab+Gemcitabine+Carboplatin/Cisplatin421
Atezolizumab Monotherapy319
Values in Percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Atezolizumab+Gemcitabine+Carboplatin/Cisplatin19.7Not reportedNot reportedNot reportedNot reported
Atezolizumab Monotherapy26.3Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1.2
      2. group Id
        OG001
        value
        0.9
    denoms
    1. counts
      1. group Id
        OG000
        value
        434
      2. group Id
        OG001
        value
        341
      units
      Participants
    title
    Baseline evaluable participants
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        19.7
      2. group Id
        OG001
        value
        26.3
    denoms
    1. counts
      1. group Id
        OG000
        value
        421
      2. group Id
        OG001
        value
        319
      units
      Participants
    title
    Post-baseline evaluable participants
denoms
  1. counts
    1. group Id
      OG000
      value
      434
    2. group Id
      OG001
      value
      341
    units
    Participants
description
Percentage of participants with Anti-Therapeutic (Anti-Atezolizumab) Antibodies (ATAs).
groups
  1. description
    Participants received blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).
    id
    OG000
    title
    Atezolizumab+Gemcitabine+Carboplatin/Cisplatin
  2. description
    Eligible participants received open-label atezolizumab as monotherapy.
    id
    OG001
    title
    Atezolizumab Monotherapy
param Type
NUMBER
population Description
The baseline ADA-evaluable population included participants who had a baseline ADA result. The post-baseline ADA-evaluable population included participants who had received at least one dose of the study treatment and who had at least one post-baseline ADA result.
reporting Status
POSTED
time Frame
Up to approximately 35 months
title
Percentage of Participants With Anti-Therapeutic (Anti-Atezolizumab) Antibodies (ATAs)
type
SECONDARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice